Tags

Type your tag names separated by a space and hit enter

Management and tolerability of glecaprevir-pibrentasvir pharmacotherapy in hepatitis C viremic heart and lung transplant recipients.
Clin Transplant. 2020 Jul 06 [Online ahead of print]CT

Abstract

We conducted a retrospective review of thoracic transplant recipients (22 heart and 16 lung transplant recipients) prospectively enrolled in a single-center observational study of HCV NAT+ organ transplantation in HCV NAT- recipients. All recipients were treated with 8 weeks of glecaprevir-pibrentasvir (GP) for HCV viremia in addition to standard triple immunosuppression post-transplant. Thoracic transplant recipients of HCV NAT- organs were used as a control (24 heart and 22 lung transplant recipients). Our primary outcome was to assess the effect of GP on tacrolimus dose requirements. Secondary objectives included assessing drug interactions with common post-transplant medications, adverse effects, and the need to hold or discontinue GP therapy. The median tacrolimus concentration-to-dose ratio (CDR) in the cohort was 184 (99-260) during GP therapy and 154 (78-304) over the first month after GP (P = .79). Trends in median tacrolimus CDR were similar on a per-week basis and per-patient basis. In three instances, concomitant posaconazole and GP led to hyperbilirubinemia and interruption of posaconazole. GP therapy was held in one heart transplant recipient and discontinued in another due to unresolving hyperbilirubinemia. Utilization of GP to treat HCV viremia post-thoracic transplant is feasible and safe, but requires modifications to post-transplant pharmacotherapy and careful monitoring for adverse effects.

Authors+Show Affiliations

Department of Pharmacy, NYU Langone Health, New York, New York, USA.Department of Cardiology, NYU Langone Health, New York, New York, USA.Department of Cardiology, NYU Langone Health, New York, New York, USA.Transplant Institute, NYU Langone Health, New York, New York, USA.Transplant Institute, NYU Langone Health, New York, New York, USA.Transplant Institute, NYU Langone Health, New York, New York, USA.Transplant Institute, NYU Langone Health, New York, New York, USA.Department of Cardiothoracic Surgery, NYU Langone Health, New York, New York, USA.Department of Cardiothoracic Surgery, NYU Langone Health, New York, New York, USA.Department of Cardiothoracic Surgery, NYU Langone Health, New York, New York, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32632929

Citation

Lewis, Tyler C., et al. "Management and Tolerability of Glecaprevir-pibrentasvir Pharmacotherapy in Hepatitis C Viremic Heart and Lung Transplant Recipients." Clinical Transplantation, 2020, pp. e14030.
Lewis TC, Gidea C, Reyentovich A, et al. Management and tolerability of glecaprevir-pibrentasvir pharmacotherapy in hepatitis C viremic heart and lung transplant recipients. Clin Transplant. 2020.
Lewis, T. C., Gidea, C., Reyentovich, A., Angel, L., Lesko, M., Pavone, J., Sureau, K., Smith, D. E., Kon, Z., & Moazami, N. (2020). Management and tolerability of glecaprevir-pibrentasvir pharmacotherapy in hepatitis C viremic heart and lung transplant recipients. Clinical Transplantation, e14030. https://doi.org/10.1111/ctr.14030
Lewis TC, et al. Management and Tolerability of Glecaprevir-pibrentasvir Pharmacotherapy in Hepatitis C Viremic Heart and Lung Transplant Recipients. Clin Transplant. 2020 Jul 6;e14030. PubMed PMID: 32632929.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management and tolerability of glecaprevir-pibrentasvir pharmacotherapy in hepatitis C viremic heart and lung transplant recipients. AU - Lewis,Tyler C, AU - Gidea,Claudia, AU - Reyentovich,Alex, AU - Angel,Luis, AU - Lesko,Melissa, AU - Pavone,Jennifer, AU - Sureau,Kimberly, AU - Smith,Deane E,3rd AU - Kon,Zachary, AU - Moazami,Nader, Y1 - 2020/07/06/ PY - 2020/01/23/received PY - 2020/06/19/revised PY - 2020/06/29/accepted PY - 2020/7/8/pubmed PY - 2020/7/8/medline PY - 2020/7/8/entrez KW - drug interactions KW - glecaprevir KW - heart transplant KW - hepatitis C KW - lung transplant KW - pibrentasvir SP - e14030 EP - e14030 JF - Clinical transplantation JO - Clin Transplant N2 - We conducted a retrospective review of thoracic transplant recipients (22 heart and 16 lung transplant recipients) prospectively enrolled in a single-center observational study of HCV NAT+ organ transplantation in HCV NAT- recipients. All recipients were treated with 8 weeks of glecaprevir-pibrentasvir (GP) for HCV viremia in addition to standard triple immunosuppression post-transplant. Thoracic transplant recipients of HCV NAT- organs were used as a control (24 heart and 22 lung transplant recipients). Our primary outcome was to assess the effect of GP on tacrolimus dose requirements. Secondary objectives included assessing drug interactions with common post-transplant medications, adverse effects, and the need to hold or discontinue GP therapy. The median tacrolimus concentration-to-dose ratio (CDR) in the cohort was 184 (99-260) during GP therapy and 154 (78-304) over the first month after GP (P = .79). Trends in median tacrolimus CDR were similar on a per-week basis and per-patient basis. In three instances, concomitant posaconazole and GP led to hyperbilirubinemia and interruption of posaconazole. GP therapy was held in one heart transplant recipient and discontinued in another due to unresolving hyperbilirubinemia. Utilization of GP to treat HCV viremia post-thoracic transplant is feasible and safe, but requires modifications to post-transplant pharmacotherapy and careful monitoring for adverse effects. SN - 1399-0012 UR - https://www.unboundmedicine.com/medline/citation/32632929/Management_and_tolerability_of_glecaprevir-pibrentasvir_pharmacotherapy_in_hepatitis_C_viremic_heart_and_lung_transplant_recipients L2 - https://doi.org/10.1111/ctr.14030 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.